Welcome to NorthShore Oncology Research. Below you will find a list of current clinical trials being conducted at Evanston, Glenbrook and Highland Park Hospitals for patients with Lung Cancer. If you would like more information on clinical trials for Lung Cancer please contact us at 847.570.1768.
Diagnosis: Advanced Small Cell Lung Cancer
Study Name and Description:
E1508:A Randomized Phase II Study of Cisplatin and Etoposide in Combination with Either Hedgehog Inhibitor GDC-0449 or IGF-A12 for Patients with Extensive Stage Small Cell Lung Cancer.
The purpose of this study is to find out what effects good and/or bad cisplatin and etoposide with or without investigational drugs known as GDC-0449 or IMC-A12 has on advanced stage small cell lung cancer. Both investigational drugs used in this study block signals in cancer cells that may be important in the growth of cancer. Researchers want to know if adding one of these two drugs to standard chemotherapy for this type of cancer will increase the effectiveness of chemotherapy or not.
Patients will be asked to undergo physical exams, blood tests, chest X-rays, CT/MRI scans and EKG's throughout participation in this study. Patients will be placed in one of three treatment groups and participation in study treatment will last approximately 1 year, doctors will want follow-up exams for 3 years.
Principal Investigator: Thomas Hensing, MD
Sponsor: Northshore University HeathSystem
Contact: Interested patients should contact Marie Neale RN, study coordinator at 847.570.2106.
Reference Number: EH09-521
Diagnosis: Metastatic Non-Small Cell Lung Cancer
Study Name and Description:
UC16574B: Randomized Phase II Trial of Docetaxel, Cisplatin and Hypofractionated Radiotherapy Versus Docetaxel, Cisplatin for Limited Volume Stage IV Non-Small Cell Lung Cancer: The Synergistic Metastases Annihilation with Radiotherapy and Docetaxel Trial.
The purpose of this study is to determine if the combination of chemotherapy and hypofractionated radiation therapy delieved shortly after diagnosis in metastatic non-small cell lung cancer patients can improve the chance of survival versus patients who recieve chemotherapy alone. Hypofractionated radiation therapy is a type of radiation therapy in which higher doses of radiation therapy are given, but in fewer fractions. In other words the dose of each individual fraction is higher, but the total dose of radiotherapy given is lower.
Patients will be asked to have physical exams, blood tests, CT/MRI/PET scans throughout participation in this study. Participation in study treatment is expected to last at least 12 weeks, and follow-up exams will be done every 3 months for life.
Principal Investigator: Thomas Hensing, MD
Sponsor: Northshore University HeathSystem
Contact: Interested patients should contact Marie Neale RN, study coordinator at 847.570.2106.
Reference Number: EH09-452
Diagnosis: Stage IIIA/IIIB Non-Small Cell Lung Cancer
Study Name and Description:
RTOG 0617-A Randomized Phase III Comparison of Standard Dose (60Gy) Versus High Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer.
The purpose of this study is to compare the effects, good and/or bad, of high-dose radiation therapy and chemotherapy with standard-dose radiation therapy and chemotherapy to find out which is better. This study will also compare the effects, good and/or bad, of adding cetuximab to radiation and chemotherapy. Cetuximab is a drug that may delay or prevent tumor growth by blocking certain cellular pathways that lead to tumor development.
Participants in this study will receive either high or low dose radiation and chemotherapy or high or low dose radiation therapy, chemotherapy and cetuximab. All participants will get chemotherapy with same drug combination and schedule. It is expected that participation in this study will last 6 or 7 1/2 weeks depending on the treatment group assigned. Participants will have follow-up visits every 3 months for first year, every 4 months for year 2 and every 6 months for year 3-5 then annually for their lifetime. Throughout participation patients will undergo physical exams, blood tests, and CT or PET scans.
Principal Investigator: Thomas Hensing, MD
Sponsor: Northshore University HeathSystem
Contact: Interested patients should contact Marie Neale RN, study coordinator at 847.570.2106.
Reference Number: EH09-178
Diagnosis: Resectable MAGE-A3-Postitive Non-Small Cell Lung Cancer
Study Name and Description:
GSK 109493: A Double Blind, Randomized, Placebo Controlled Phase III Study To Assess the Efficacy of RecMAGE-A3 + ASCI Antigen-Specific Cancer Immunotherapeutic As Adjuvant Therapy in Patients with Resectable MAGE-A3-Postitive Non-Small Cell Lung Cancer.
The purpose of this study is to test an investigational treatment to see if it may prevent recurrence of cancer after a patient has undergone surgery. The study product that will be administered is call antigen-specific cancer immunotherapeutic (ASCI). By using a protein specific of the cancer (antigen specific), this study product will use the immune system to try and fight the cancer (cancer immunotherapeutic). The way this investigational product works is based upon immunization. It may stimulate your own body to fight cancer in the same way that is fights an infection by germs or viruses.
To be eligible for this study, your cancer needs to have certain “immune” characteristics which are referred to by scientist and clinicians as MAGE-A3. Only about 35% of people with lung cancer produce the MAGE-A3 protein and this production will be checked to see if you are one of those who might benefit. If your cancer does not contain MAGE-A3, you will not be eligible to participate in this research study. Eligible patient (those that have cancer that contains MAGE-A3) will receive administration of either ASCI or placebo. Each subject entering the study will have 2 out of 3 chances to receive ASCI and 1 out of 3 chances of receiving placebo. Throughout participation, CT scans, chest x-rays, and blood test will be done. The study treatment will last 27 months from the first to last treatment administration. After that, patients will have follow-up office visits every 6 months for the first 5 years and then a follow-up phone call once a year for another five years
Principal Investigator: Thomas Hensing, MD
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact Marie Neale RN, study coordinator at 847.570.2106.
Reference Number: EH08-223
Diagnosis: Stage IIIB/IV Non-Small Cell Lung Cancer
Study Name and Description:
LCCC 0512: Randomized Phase II Study of First Line Treatment with Gemcitabine vs. Erlotinib vs. Gemcitabine and Erlotinib in Elderly Patients With Stage IIIB/IV Non-Small Cell Lung Cancer.
The purpose of this study is to observe how long this treatment will prevent progression of the stage IIIB/IV non-small cell lung cancer in elderly patients treated with gemcitabine alone or erlotinib alone or combination gemcitabine and erlotinib, and to determine if we are able to predict response.
Participants in this study will receive treatment with two drugs, gemcitabine and erlotinib. Gemcitabine is a standard chemotherapy agent in the treatment of non-small cell lung cancer. Eroltinib works differently than other chemotherapy drugs; it is a drug that has shown promising activity against a number of types of cancer. Because erlotinib works differently from the way other chemotherapy drugs work, researches believe that combining gemcitabine and erlotinib may have added benefit. Giving gemcitabine and erlotinib at the same time is considered investigational and is not approved by the FDA.
Treatment will last for at least 4 months. Throughout treatment, participants will receive physical exams, blood tests and CT scans. Follow-up visits will occur every 2 months for 3 years during which physical exams, blood test and CT scan will continue to be done. Participants will also be asked to have their tumor tested for a certain mutation, and to have blood taken to help determine if gemcitabine or erlotinib may work better with certain mutations in tumor cells or normal cells in the body.
Principal Investigator: Thomas Hensing, MD
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact Marie Neale RN, study coordinator at 847.570.2106.
Reference Number: EH06-376
Diagnosis: Resected Stage IB-IIIA Non-Small Cell Lung Cancer
Study Name and Description:
ECOG 1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage IB (> 4cm) –IIIA Non-Small Cell Lung Cancer.
The purpose of this study is to determine if adding a new drug called bevacizumab to standard chemotherapy improves the chance for cure in patients who have had surgery for the removal of lung cancer.
Bevacizumab works by preventing the formation of new blood vessels, which may reduce tumor cell growth and cause cancerous tumors to grow more slowly or shrink.
Bevacizumab is approved by the FDA for use in advanced non-small cell lung cancer. It is not approved for use in early stage lung cancer and it therefore investigational in this study.
Participants in this study have non-small cell lung cancer, and have had surgery to remove lung cancer. Participants will receive either standard chemotherapy or standard chemotherapy with bevacizumab. Periodically throughout study treatment physical exams, blood tests, chest x-rays and other medical tests and procedures will be performed. Treatment is expected to last anywhere from 3 months to 1 year. After treatment, participants will have follow-up visits for approximately 10 years, during which health status information with be collected.
Principal Investigator: Thomas Hensing, MD
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact Marie Neale RN, study coordinator at 847.570.2106.
Reference Number: EH07-393
Diagnosis: Small Cell Lung Cancer
Study Name and Description:
CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens, in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide.
The purpose of this study is to compare the effects, good and/or bad, of three different ways to give radiation therapy. Two ways are investigational, while one of them is standard of care for this disease.
Participants in this study have small cell lung cancer that has not been detected out side of the chest. All participants will receive chemotherapy with cisplatin and etoposide, which is standard chemotherapy for this type of cancer. Participants will also get radiation therapy one of three ways: (1) once a day with high dose radiation for 7 weeks, (2) once a day for 16 days of treatment (about 3 weeks), followed by twice a day for the remaining 9 days of treatment (about 3 weeks) for a total of 5 weeks, or (3) the standard of care radiation therapy twice a day for 3 weeks.
During the study, physical exams, blood test, CT scans and pulmonary function tests will be done. Participation in this study is expected to last 3-4 months with follow-up examinations every 3 months for 2 years, every 6 months for 3 years and every 12 months for 5 years.
Principal Investigator: Thomas Hensing, MD
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact Marie Neale RN, study coordinator at 847.570.2106.
Reference Number: EH08-417
Diagnosis: Advanced Stage IIIB/IV Non-Small Cell Lung Cancer.
Study Name and Description:
CALGB 30607: Randomized, Phase III, Double-Blind Placebo Controlled Trial of Sunitinib (NSC#736511, IND#74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer.
The purpose of this study is to determine whether or not a drug called sunitinib given after chemotherapy will help tumors to continue to shrink or stay the same. Sunitinib is FDA approved for the treatment of renal cancer, but it is investigational in the treatment of non-small cell lung cancer. The standard of care treatment for this type of cancer would be to stop chemotherapy treatment after the initial therapy.
Participants in this study have advanced stage non-small cell lung cancer that has been treated by chemotherapy. Participants will receive the study treatment as long as the cancer does not grow or spread and there are no serious side effects from study drugs. Throughout the study physical exams, and CT scans of the chest and nearby organs will be done every 3 months for 1 year, then every 6 months for 3 years.
Principal Investigator: Thomas Hensing, MD
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact Marie Neale RN, study coordinator at 847.570.2106.
Reference Number: EH09-088